Explore how OCD and schizophrenia overlap, complicating diagnosis and care, and learn spectrum-based strategies and treatment pitfalls for managing schizo-obsessive symptoms.
|Articles|October 16, 2012
Twitter feed Psychiatric Times Coverage of HMP Global, LLC’s Psych Congress® Conference 2012
Listen
0:00 / 0:00
Key Takeaways
- Source material is derived from Psych Congress® presentations and then shaped into articles and interviews by Psychiatric Times editors and contributors.
- Independence is emphasized through clear statements of no affiliation, endorsement, or sponsorship by third parties.
Advertisement
The articles and interviews featured on this page were developed by Psychiatric Times editorial staff and contributors based on presentations delivered at Psych Congress®, an annual conference produced by HMP Global, LLC. Psychiatric Times is an independent publication and is not affiliated with, endorsed by, or sponsored by HMP Global, LLC. All content on this page reflects the independent editorial judgment of Psychiatric Times and does not represent the views, positions, or communications of HMP Global, LLC.
Advertisement
Related to this article
How estrogen dips during menstruation, pregnancy, postpartum, and menopause can trigger schizophrenia relapse, and what it means for antipsychotic dosing.
Psychiatric Times honors those who served with reflections from a World War I diary and new studies on veteran PTSD and suicide risk.
Cingulate shares plans to resubmit its ADHD candidate CTx-1301 to the FDA, following a CRL tied to CMC information requests
The American Society of Addiction Medicine has released the first clinical guide and national resource for managing the intoxication and withdrawal of medetomidine.
Digital memory tests flag subtle preclinical Alzheimer changes, especially with neocortical tau; scalable tools may boost future trial screening.
How ED physicians and psychiatrists team up to cut mental health boarding, reduce unnecessary tests, and deliver faster, safer ED crisis care.
In the second positive phase 3 trial of lumateperone (Caplyta) for bipolar mania, participants saw improved manic symptoms vs placebo as early as day 3.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Cannabis Use Prevalent In Substance-Related Adolescent Emergency Care: Insights From Kevin Xu, MD
2
Schizo-Obsessed! Untangling the Overlap Between Obsessive Compulsive Disorder and Schizophrenia
3
Lumateperone Shows Significant and Rapid Improvement in Bipolar Mania
4
Promoting Literacy to Improve Child Development: Reading Model Boosts Efforts
5